Drug Profile
Ivermectin long acting injectable - Medincell
Alternative Names: mdc-STM; mdc-TTGLatest Information Update: 13 Nov 2023
Price :
$50
*
At a glance
- Originator MedinCell S.A.
- Developer MedinCell S.A.; Monash University
- Class Antimalarials; Antineoplastics; Antiparasitics; Antivirals; Macrolides; Skin disorder therapies; Small molecules
- Mechanism of Action Chloride channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections
- Preclinical Malaria
Most Recent Events
- 06 Nov 2023 MedinCell plans a phase I clinical trial for Malaria in 2024
- 28 Oct 2023 No recent reports of development identified for phase-I development in COVID-2019-infections(In volunteers) in United Kingdom (PO)
- 05 Jan 2023 Adverse events and efficacy data from the phase-III SAIVE trial in COVID-19 infections released by MedinCell